Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323652 | 0.79 | KDM4E (0.60) | KDM4EDNMT1SMN1; SMN2 | |
| SCHEMBL18323645 | 0.76 | POLB (0.57) | KDM4EPOLBDNMT1 | |
| SCHEMBL18323636 | 0.73 | KDM4E (0.41) | KDM4EPOLBDNMT1 | |
| SCHEMBL18323644 | 0.68 | KDM4E (0.55) | KDM4EDNMT1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL18323693 | 0.65 | KDM4E (0.39) | KDM4EPOLBSMN1; SMN2KMT2A | |
| SCHEMBL18323657 | 0.65 | KDM4E (0.60) | KDM4EDNMT1SMN1; SMN2KMT2A | |
| SCHEMBL11775977 | 0.61 | KDM4E (0.56) | KDM4EPOLBSMN1; SMN2KMT2AMAPT | |
| SCHEMBL18323632 | 0.61 | KDM4E (0.55) | KDM4EDNMT1SMN1; SMN2 | |
| SCHEMBL18323677 | 0.59 | POLB (0.57) | KDM4EPOLBKMT2ASHMT2MAPT | |
| SCHEMBL936095 | 0.57 | POLB (0.66) | KDM4EPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |